Drug Trial Radar · NCT07775846
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
820
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Feb 28, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Huijie ZhangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all participants will be randomized in a 1:1:1:1 ratio into four treatment groups: Group 1 (G1): ARB + empagliflozin + finerenone placebo + mazdutide placebo; Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide placebo; Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone placebo; Group 4 (G4): ARB + empagliflozin + mazdutide + finerenone. The primary comparisons include G2 vs. G1, G3 vs. G1, G4 vs. G2, and G4 vs. G3, designed to evaluate the superiority of triple therapy over dual therapy, and quadruple therapy over triple therapy, in reducing the urine albumin-to-creatinine ratio (UACR).
Conditions
- Type 2 Diabetic Kidney Disease
Interventions
empagliflozinDrug
Oral tablet, administered at a fixed dose of 10 mg once daily for 6 months.
FinerenoneDrug
Oral tablet, taken once daily for 6 months. Initial dose is 10 mg or 20 mg once daily adjusted based on baseline eGFR (20 mg for eGFR \>= 60 mL/min/1.73m²; 10 mg for eGFR 30-60 mL/min/1.73m²). Subsequent dose adjustments are guided by serum potassium levels and renal function.
MazdutideDrug
Once-weekly subcutaneous injection for 6 months, following a mandatory dose-escalation schedule: initiated at 2 mg once weekly for 4 weeks, up-titrated to 4 mg once weekly for 4 weeks (if tolerated), and further increased to 6 mg once weekly as the target maintenance dose.
Finerenone PlaceboDrug
Oral tablet matching active finerenone in appearance and scheduling, without active ingredients, taken once daily for 6 months.
Mazdutide PlaceboDrug
Once-weekly subcutaneous injection matching active mazdutide in appearance and scheduling, without active ingredients, for 6 months.
Angiotensin Receptor Blocker (ARB)Drug
Standard background therapy, titrated to a stable dose for at least 4 weeks prior to enrollment and maintained throughout the 6-month study period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Month 6Time frame: Baseline and Month 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.